Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Investing Activities (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Cash from Investing Activities data on record, last reported at -$135.7 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 360.69% year-over-year to -$135.7 million; the TTM value through Dec 2025 reached -$40.9 million, down 147.45%, while the annual FY2025 figure was -$40.9 million, 147.45% down from the prior year.
  • Cash from Investing Activities reached -$135.7 million in Q4 2025 per TNGX's latest filing, down from $47.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $52.1 million in Q4 2024 and bottomed at -$152.2 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$3.5 million, with a median of $16.0 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: surged 635.74% in 2022, then tumbled 472.1% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$45.2 million in 2021, then skyrocketed by 72.12% to -$12.6 million in 2022, then soared by 368.56% to $33.9 million in 2023, then surged by 53.79% to $52.1 million in 2024, then plummeted by 360.69% to -$135.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$135.7 million in Q4 2025, $47.5 million in Q3 2025, and $16.8 million in Q2 2025.